Beranda › Leukemia
Uji klinis Leukemia yang merekrut di AS
102 studi untuk Leukemia merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX28 studi
- Boston, MA25 studi
- New York City, NY19 studi
- Chicago, IL16 studi
- Los Angeles, CA16 studi
- Durham, NC13 studi
- Columbus, OH12 studi
- Nashville, TN12 studi
- Baldwin Park, CA12 studi
- Philadelphia, PA12 studi
- Atlanta, GA11 studi
- Seattle, WA11 studi
- Milwaukee, WI11 studi
- Birmingham, AL10 studi
- Aurora, CO10 studi
- Miami, FL9 studi
- Edison, NJ9 studi
- Mountain View, CA9 studi
- Cincinnati, OH9 studi
- New Haven, CT8 studi
- Dallas, TX8 studi
- Queens, NY8 studi
- Portland, OR8 studi
- Orange, CA7 studi
- Denver, CO7 studi
- Buffalo, NY7 studi
- Clifton, NJ7 studi
- Washington, DC7 studi
- Tampa, FL7 studi
- Cedar Rapids, IA6 studi
- Omaha, NE6 studi
- Charlottesville, VA5 studi
- Charlotte, NC5 studi
- Cleveland, OH5 studi
- Memphis, TN5 studi
- Rochester, MN5 studi
- Baltimore, MD5 studi
- Ann Arbor, MI5 studi
- San Diego, CA5 studi
- St. Louis, MO4 studi
Berdasarkan negara bagian
- Alabama10 studi
- Arizona7 studi
- California28 studi
- Colorado15 studi
- Connecticut11 studi
- Florida17 studi
- Georgia13 studi
- Illinois17 studi
- Indiana4 studi
- Iowa7 studi
- Kansas5 studi
- Kentucky6 studi
- Louisiana3 studi
- Maine3 studi
- Maryland11 studi
- Massachusetts28 studi
- Michigan8 studi
- Minnesota9 studi
- Missouri6 studi
- Nebraska6 studi
- New Jersey15 studi
- New Mexico3 studi
- New York26 studi
- North Carolina20 studi
- Ohio26 studi
- Oklahoma4 studi
- Oregon9 studi
- Pennsylvania15 studi
- Rhode Island4 studi
- South Carolina6 studi
- Tennessee14 studi
- Texas31 studi
- Utah4 studi
- Vermont4 studi
- Virginia7 studi
- Washington11 studi
- Wisconsin13 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Rutgers University Study of the Genetics of Blood Cancers
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07714044Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Menerima pesertaStudi observasional
Usia 18 hingga 110 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT00923507Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Menerima pesertaFase 3
Usia 18 hingga 71 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Menerima pesertaFase 2
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05645718Natural History Study of GATA2 Deficiency and Related Disorders
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 2 hingga 100 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT01905826A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Menerima pesertaFase 1/2
30 Days · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06824168Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Menerima pesertaFase 1
Hingga usia 75 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06345027(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04996875A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Menerima pesertaFase 1
Hingga usia 25 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06810583A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06229912Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Menerima pesertaFase 3
Usia 18 hingga 18 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07509151Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Menerima pesertaFase 2
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07354074Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07249346First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07586618Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Menerima pesertaFase 1
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06408194Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 5 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT05237986Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07284433CIML NK Cells With Venetoclax for AML
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Menerima pesertaFase 1
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT07439211Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Menerima pesertaFase 1
18 Months – 39 Years · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT07573111Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07007312Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.